TickerTalks
Browse all tickers →
TickerTalks›$AVTR
AVAVTR

Avantor, Inc.

Rising onWhy it's trendingX chatter spiked vs its recent norm
$AVTR·$6.6B·Medical - Instruments & Supplies·Healthcare
$9.57-0.9%YTD-16.1%1Y-28.6%
Mentions · last 7 days
2026-06-05: 12 posts2026-06-06: 15 posts2026-06-07: 33 posts2026-06-08: 129 posts2026-06-09: 106 posts2026-06-10: 135 posts2026-06-11: 96 posts527+22%
Price updated 12m ago·X counts updated 21h ago
AVAVTR
Avantor, Inc.$AVTR
$9.58-0.88%527 posts+22%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AVTR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-06-12

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Life-sciences-tools company at 28th pct of 52w — multiple C-suite changes signaling operational reset, Q1 revenue flat YoY.

Avantor is the lab-services and life-sciences-tools company — provider of laboratory products and services to pharma and biotech customers. The stock has been crushed but the operational reset is showing through with multiple C-suite changes and stabilization signals. Q1 revenue was flat YoY at $1.58B at 7.3% operating margin and EPS of $0.06 — the topline stabilization the Seeking Alpha framing references, with FCF yield of 6.7% on the underlying cash generation. At 1.0x trailing sales the multiple has compressed deeply for a healthcare-services name. The April 17 announcement that Benoit Gourdier (EVP Bioscience and Medtech Products) would transition out by December 31, 2026, and April 23 hiring of Ludovic Brellier as EVP Bioscience and Medtech Products and Chief Transformation Officer signals the strategic transformation step. The May 19 Gerard Porreca EVP Quality and Regulatory appointment extends the leadership rebuild. Insider activity is only governance-related. The May 7 Annual Meeting saw notable withhold votes against directors Louise Makin (26.6M against) and Joseph Massaro (29.4M against) — material proxy signals.

What to watch: Aug 7 Q2 print — segment revenue trajectory (Bioscience vs Equipment & Instruments vs Lab Solutions), gross margin direction, and any commentary on the EVP Brellier strategic transformation plans. Continued leadership-rebuild execution under the new structure is the structural variable.

On the calendar: 2026-08-07 — Q2 earnings

no sentiment

Read the AI verdict + X sentiment for $AVTR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $AVTR.

Medical - Instruments & Supplies · Healthcare

Medline's prime vendor model expanding internationally and the hospital supply chain consolidation are the structural drivers — large-scale medical-surgical supply distributors benefit from hospital systems seeking single-source supply chain simplification. Secondary offering close confirms institutional demand for Medline.

See how Medical - Instruments & Supplies shapes $AVTR

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $AVTR's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Industry benchmark

9-name peer basket
+5.3%YTD
+3.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-2.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-4.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-9.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
32.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$0.17$0.16+6.3%
Q4 2025Feb 11, 2026$0.22$0.21+4.8%
Q3 2025Oct 29, 2025$0.22$0.22-2.1%
Q2 2025Aug 1, 2025$0.24$0.25-4.0%
Next earningsFri, Aug 7·consensus EPS $0.19

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.6B0.0%31.7%7.3%$0.06$25.2M
Q4 FY25$1.7B-1.4%31.5%7.6%$0.08$117.2M
Q3 FY25$1.6B-5.3%32.4%-40.0%$-1.04$171.7M
Q2 FY25$1.7B-1.1%32.9%7.7%$0.09$124.8M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$6.5B$6.5B – $6.5B$0.79$0.78 – $0.8012
FY27$6.6B$6.6B – $6.7B$0.85$0.81 – $0.8912
FY28$6.8B$6.8B – $6.9B$0.91$0.80 – $1.089
FY29$7.1B$7.0B – $7.2B$0.98$0.98 – $1.004
FY30$7.4B$7.3B – $7.4B$1.04$1.03 – $1.054

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+15.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 661.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.965-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $AVTR is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 8Gregory T LucierDirector10.0K sh$83KBuyMay 1Simon DingemansDirector25.0K sh$204KBuyMar 10Sanjeev K MehraDirector125.0K sh$1.0MBuyFeb 19Gregory T LucierDirector50.0K sh$458KBuyFeb 12Gregory L SummeDirector100.0K sh$940K
+ 32 other (19 awards · 13 inkinds) in window

See when $AVTR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 128-K — Item 5.07: Shareholder vote
AI summary

Avantor, Inc. (AVTR) held its 2026 Annual Meeting on May 7, 2026, electing nine directors to one-year terms; notable withhold votes were cast against Louise Makin (26.6 million against vs. 593.5 million for) and Joseph Massaro (29.4 million against vs. 590.9 million for), the highest dissent in the visible excerpt, likely reflecting proxy advisor concerns on board composition or committee assignments. Other nominees including Simon Dingemans (97.5% support) and Emmanuel Ligner received broad majority support. This is a routine governance filing; elevated but minority withhold votes against two directors do not change election outcomes but may prompt board engagement with investors.

3New insider — initial holdingsMay 53
AI summary

Ludovic Brellier filed a Form 3 initial beneficial ownership statement as a newly appointed Officer of Avantor, Inc. (AVTR), with an event date of May 1, 2026, consistent with his appointment as Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer effective that date. No ownership position is detailed in the available excerpt. This is a routine officer-entry administrative filing.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Avantor, Inc. (AVTR) disclosed on April 17, 2026 that Benoit Gourdier (EVP, Bioscience and Medtech Products) would transition to a supporting integration role and depart no later than December 31, 2026, and on April 23, 2026 announced the hiring of Ludovic Brellier as EVP Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026. Gourdier's departure and Brellier's hire represent a material leadership change in Avantor's key Bioscience segment; Brellier's additional title of Chief Transformation Officer signals an active segment integration initiative as a named strategic priority.

8-KOfficer or director changeApr 18-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-K/AOfficer or director change (amended)Feb 258-K/A — Item 5.02: Officer or director change
8-K/AOfficer or director change (amended)Feb 258-K/A — Item 5.02: Officer or director change
8-KPress release / Reg FDFeb 118-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
3New insider — initial holdingsJan 123
+ 10 other (2 13Gs · 2 proxys · 1 SD · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Is Avantor (AVTR) Up 13% Since Last Earnings Report?zacks.com·14d agoHere's Why You Should Hold Avantor Stock in Your Portfolio for Nowzacks.com·14d agoAvantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatoryprnewswire.com·25d agoAvantor Q1 Earnings & Revenues Beat Estimates, Margins Declinezacks.com·43d agoAvantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visibleseekingalpha.com·43d ago

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MDLN$BDX$ZTEK$WRBY$WST$PLSE$RGEN$AZTA
Voices on X · last 7 days

No standout posts about $AVTR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport